# Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia

> **NCT02363075** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 58 (estimated)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Dexamfetamine sulphate
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02363075
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-04
- **Primary completion:** 2017-07
- **Final completion:** 2018-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363075, "Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02363075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*